1. Mild or moderate Alzheimer-type dementia treatment.
Donepezil hydrochloride is a long-acting Alzheimer's disease (AD) in the symptomatic treatment drugs. AD is a kind of memory loss as the main performance, accompanied by other cognitive impairment of acquired intelligence decline.

2. Donepezil hydrochloride is a second-generation cholinesterase (CHE) inhibitor, its therapeutic effect is reversibly inhibiting acid hydrolysis of acetylcholine acetylcholinesterase (ACHE) caused by increased content of acetylcholine receptor sites.

3. Donepezil may have other mechanisms, including the disposal of the direct effect of the peptide, neurotransmitter receptors.

4.Donepezil hydrochloride selection of AchE affinity than to butyrylcholinesterase (BCHE) 1250 times stronger, it can inhibit the brain tissue CHE, but on the heart (myocardium) or small intestine (smooth) had no effect, probably on the chest organization (rhabdomyosarcoma) role; on the central nervous toxicity than tacrine.
 

1. General info:Donepezil (also misspelled donezepil),  is a centrally acting reversible acetylcholinesterase inhibitor. Its main therapeutic use is in the treatment of Alzheimer's disease where it is used to increase cortical acetylcholine. Its binding to the acetylcholinesterase can be seen at Proteopedia 1eve. It has an oral bioavailability of 100% and easily crosses the blood-brain barrier. Because it has a half life of about 70 hours, it can be taken once a day. Initial dose is 5 mg per day, which can be increased to 10 mg per day after an adjustment period of at least 4 weeks, and then after 3 months can be titrated to 23mg if needed.

2.Other indications: Donepezil has been tested in other cognitive disorders (and is sometimes used off label) including Lewy body dementia and vascular dementia, but it is not currently approved for these indications. Donepezil has been found to improve sleep apnea in Alzheimer's patients. Donepezil has also been studied in patients with Mild Cognitive Impairment, schizophrenia, attention deficit disorder, post-coronary bypass cognitive impairment, cognitive impairment associated with multiple sclerosis, CADASIL, and Down syndrome. A 3 year NIH trial in patients with mild cognitive impairment reported that donepezil was superior to placebo in delaying rate of progression to dementia during the initial 18 months of the study but this was not sustained at 36 months. In a secondary analysis, a subgroup of individuals with the Apolipoprotein E4 genotype showed sustained benefits with donepezil throughout the study. However at this time donepezil is not indicated for prevention of dementia. Recent studies suggest that Donepezil can improve speech in children with autism. The studies found that speech of autistic children who were mild to moderately affected appeared to improve from the use of Donepezil.